Overview
Hybridoma: A Journal of Molecular Immunology and Experimental and Clinical Immunotherapy, presents the latest developments in characterization and production of monoclonal antibodies. Hybridoma is the essential online journal for scientists and clinicians in the fields of molecular immunology and immunopathology, and for all those applying molecular immunological methods for experimental and therapeutic purposes.
Fully refereed, peer-reviewed articles and short communications present current findings in the development and characterization of mAbs across all therapeutic areas. Development of mAbs for all research applications, including probes, inhibitors, and diagnostic reagents, is also described.
Hybridoma covers:
- Isolation and production methods
- Characterization, epitope mapping
- Delivery systems for immunotherapeutic and experimental purposes
- Application of mAbs to elucidate signaling pathways
- Development of immunotherapeutic compounds
- Generation of probes for molecular monitoring
- Creation of diagnostic reagents, experimental and clinical
- Analysis of mAb antagonistic/inhibitory effects
- Cellular and molecular responses to mAb immunization
- Immunoscreening for identification of molecular variants and markers
- New sources for availability of fully characterized mAbs
Hybridoma is under the editorial leadership of Editor Zenon Steplewski, Department of Cancer Biology, Thomas Jefferson University, Jefferson Medical College, and other leading investigators. View the entire editorial board.
Audience: Cell biologists, immunologists, molecular biologists, among others